Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 1/20 | 0.61 |
| ▸ | FKBP1A | P62942 | 9/20 | 0.60 |
| ▸ | PREP | P48147 | 5/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9610764 | 1.00 | KLK7 (0.61) | KLK7FKBP1APREPMEN1KMT2A | |
| SCHEMBL7307432 | 1.00 | KLK7 (0.61) | KLK7FKBP1APREPMEN1KMT2A | |
| SCHEMBL6925800 | 0.98 | FKBP1A (0.64) | KLK7FKBP1APREPMEN1KMT2A | |
| SCHEMBL159105 | 0.96 | KLK7 (0.66) | KLK7FKBP1APREPMEN1KMT2A | |
| SCHEMBL5970730 | 0.96 | KLK7 (0.66) | KLK7FKBP1APREPMEN1KMT2A | |
| SCHEMBL159104 | 0.96 | KLK7 (0.66) | KLK7FKBP1APREPMEN1KMT2A | |
| SCHEMBL13257218 | 0.92 | FKBP1A (0.70) | KLK7FKBP1APREPMEN1KMT2A | |
| SCHEMBL16531226 | 0.92 | FKBP1A (0.70) | KLK7FKBP1APREPMEN1KMT2A | |
| SCHEMBL221644 | 0.92 | FKBP1A (0.70) | KLK7FKBP1APREPMEN1KMT2A | |
| SCHEMBL10522061 | 0.91 | PREP (0.64) | KLK7FKBP1APREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8674144-B2 | Catalyst for asymmetric hydrogenation and method for manufacturing optically active carbonyl compound using the same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2014-03-18 | — | — | US | disclosed |
| US-8674144-B2 | Catalyst for asymmetric hydrogenation and method for manufacturing optically active carbonyl compound using the same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2014-03-18 | — | — | US | disclosed |
| US-20120136176-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE CARBONYL COMPOUND USING THE SAME | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136176-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE CARBONYL COMPOUND USING THE SAME | HMOX1, HIRA, HRH1 | KLK7 569/4885FKBP1A 2178/4885PREP 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.